Systematic review reveals 16.8% prevalence of ESBL-producing bacteria in West Africa, indicating urgent need for antimicrobial resistance strategies.
Extended-spectrum beta-lactamase (ESBL)-producing bacteria are associated with life-threatening infections with limited treatment options worldwide. In this review, we assess the circulating ESBL-producing bacterial clones from human, animal, and environmental sources in West Africa, through a One Health approach. A systematic search in PubMed, Scopus, and Web of Science identified 485 records, with 38 studies analysed. Data were organized thematically and pooled prevalence estimates calculated through a random-effects meta-analysis. Results showed a 16.8% (95% CI [12.1; 22.1]) prevalence of ESBL-producing bacteria, with Escherichia coli (64%) being the most frequently detected species. Humans were the most affected (20.4%), followed by animals (12.8%) and the environment (9.3%). Among the 153 identified bacterial clones, ST10, ST410, ST58, ST155, ST4684, ST2178, and ST37, found majorly in E. coli, occurred across multiple sources, suggesting cross-sectoral transmission. The blaCTX-M gene, prevalent with several fluoroquinolone and aminoglycoside resistance genes, was often on conjugative IncF plasmids (50.0%), suggesting high horizontal transmission potential. The emerging ESBL gene, GES (1.2%) was also detected in Pseudomonas aeruginosa. The findings reinforce the need for robust antimicrobial resistance monitoring and intervention strategies in West Africa. A regional One Health-based approach is necessary to curtail the spread of resistant bacterial clones and safeguard the efficacy of available treatment options.
No takes yet. Share an insight, caveat, or question.
Yartey et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: